昆药集团 (600422.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

14.4x

Market Cap

CNY 6.29B

MomentumView details →

1D Return

−2.69%

YTD Return

−32.40%

RSI (14)

44.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

14.4x

Market Cap

CNY 6.29B

RSI (14)

44.5

MomentumView details →

1D Return

−2.69%

YTD Return

−32.40%

ProfitabilityView details →

Gross Margin

36.67%

Net Margin

2.03%

EBITDA Margin

10.74%

ROE (TTM)

2.25%

ROA (TTM)

1.05%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

−28.21%

EPS YoY

−81.11%

FCF YoY

—

Revenue CAGR 3Y

−7.40%

EPS CAGR 3Y

−3.38%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.29

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

2.09x

Quick Ratio

1.64x

Div Yield

2.12%

Div Rate

CNY 0.18

Div Growth 1Y

−40.00%

Financials snapshotView financials →

Revenue (TTM)

5.80B

Net Income (TTM)

117.67M

Op. CF (TTM)

−185.01M

Next earningsOct 26, 2026 →

Latest newsMore news →

Kunming Pharma Group received regulatory acceptance to register medium-term notes of up to 1 billion yuan, valid for two years, with phased issuance allowed.4d ago

Kunming Pharma Group reported first-half 2026 revenue of 1.643 billion yuan, down 50.97% year-on-year, and a net loss attributable to shareholders of 364 million yuan, down 283.48% year-on-year.15d ago

Similar companies

China Shineway Pharmaceutical Group Limited02877.HK Shenzhen Hepalink Pharmaceutical Group Co., Ltd.09989.HK 辰欣药业603367.SH 亚虹医药-U688176.SH Lantheus Holdings, Inc.LNTH 百克生物688276.SH Find similar companies →

Latest newsMore news →

Kunming Pharma Group received regulatory acceptance to register medium-term notes of up to 1 billion yuan, valid for two years, with phased issuance allowed.4d ago Kunming Pharma Group reported first-half 2026 revenue of 1.643 billion yuan, down 50.97% year-on-year, and a net loss attributable to shareholders of 364 million yuan, down 283.48% year-on-year.15d ago